Nearly two months after inking a licensing deal worth up to $1.5 billion with Swiss pharma giant Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round that will support the development of the company’s pipeline of novel T cell engagers (XPATs) and cytokines (XPACs).